Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Sponsors
Karolinska University Hospital, Karyopharm Therapeutics Inc., Medica Scientia Innovation Research S.L., Hospices Civils De Lyon
Conditions
Advanced HR[+]/HER2[–] breast cancer.Advanced triple-negative breast cancer (TNBC)Lyell syndromeNon-metastatic HER2-positive Breast CancerRelapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)Stevens Johnson syndrome
Phase 2
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
RecruitingCTIS2022-501504-95-00
Start: 2023-06-23Target: 402Updated: 2025-08-18
Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative or Luminal Breast Cancer. – The PRIMED Study –
CompletedCTIS2024-514060-10-00
Start: 2023-02-02End: 2025-11-05Target: 50Updated: 2025-10-03
Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes)
RecruitingCTIS2024-515275-35-00
Start: 2022-05-13Target: 42Updated: 2025-06-27
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-
Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL).
Active, not recruitingCTIS2024-513616-95-00
Start: 2020-12-22Target: 60Updated: 2025-10-02